Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
暂无分享,去创建一个
A. Prasse | T. Welte | F. Herth | M. Kreuter | S. Gläser | C. Grohé | S. Andreas | L. Hagmeyer | J. Klotsche | D. Pittrow | M. Schwaiblmair | C. Neurohr | D. Skowasch | H. Wilkens | T. Bahmer | M. Frankenberger | J. Swigris | J. Behr | H. Wirtz | M. Held | M. Claussen | D. Koschel | Joachim F. Meyer | S. Geier | J. Kirschner | T. Bahmer
[1] Mark G. Jones,et al. Accuracy Of A Clinical Diagnosis Of Idiopathic Pulmonary Fibrosis: A Study Of 275 Pulmonologists From 54 Countries , 2017 .
[2] F. Martinez,et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study , 2017, European Respiratory Journal.
[3] W. Cooper,et al. Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry , 2017, Respirology.
[4] M. Ando,et al. The St. George’s Respiratory Questionnaire as a prognostic factor in IPF , 2017, Respiratory Research.
[5] S. Birring,et al. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen , 2016, Pneumologie.
[6] K. Brown,et al. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis , 2016, Patient related outcome measures.
[7] A. Warth,et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis , 2016, PloS one.
[8] G. Raghu,et al. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. , 2016, Chest.
[9] J. Beaumont,et al. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis , 2016, Lung.
[10] G. Raghu,et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis , 2016, BMC Medicine.
[11] T. Welte,et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry , 2015, European Respiratory Journal.
[12] K. Brown,et al. The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review , 2014, Health and Quality of Life Outcomes.
[13] R. Sussman,et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[14] J. Yorke,et al. Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA) , 2014, BMJ Open Respiratory Research.
[15] K. Albright,et al. A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis , 2014, BMJ Open Respiratory Research.
[16] J. Behr,et al. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry , 2014, BMJ Open Respiratory Research.
[17] M. Horton,et al. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. , 2013, Chest.
[18] H. Collard,et al. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan , 2013, Annals of Internal Medicine.
[19] I. Higginson,et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature , 2012, Thorax.
[20] M. Kreuter,et al. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. , 2012, Deutsche medizinische Wochenschrift.
[21] K. Anstrom,et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. , 2012, Respiratory medicine.
[22] Joyce S Lee,et al. A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.
[23] S. Birring,et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire , 2012, Thorax.
[24] T. Marras,et al. Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. , 2011, Canadian respiratory journal.
[25] P. Jones,et al. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire , 2010, Thorax.
[26] H. Collard,et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.
[27] Meilan K. Han,et al. Gender influences Health-Related Quality of Life in IPF. , 2010, Respiratory medicine.
[28] S. Sahn,et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.
[29] Zhen-hua Li,et al. Cross‐sectional and longitudinal construct validity of the Saint George's Respiratory Questionnaire in patients with IPF , 2008, Respirology.
[30] M. Neary,et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.
[31] J. Norris,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. , 2007, American journal of respiratory and critical care medicine.
[32] J. M. Salge,et al. Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[33] R. Kaplan,et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. , 2005, Journal of cardiopulmonary rehabilitation.
[34] Y. Kondoh,et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? , 2005, Respiratory medicine.
[35] A. Ries,et al. Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale , 2005, COPD.
[36] G. Raghu,et al. Assessment of health-related quality of life in patients with interstitial lung disease. , 1999, Chest.
[37] P. Jones,et al. The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.
[38] S. Birring,et al. [German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"]. , 2016, Pneumologie.
[39] A. Azuma,et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .
[40] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.
[41] Shandra L. Protzko,et al. AMERICAN THORACIC SOCIETY DOCUMENTS An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline , 2015 .
[42] Shandra L. Protzko,et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline , 2015 .
[43] A. Russell,et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. , 2011, Chest.
[44] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .